LLY

1,083.2

+0.58%↑

JNJ

208.29

+0.39%↑

ABBV

230.62

+0.2%↑

UNH

329.49

-0.63%↓

AZN

92.7

-0.2%↓

LLY

1,083.2

+0.58%↑

JNJ

208.29

+0.39%↑

ABBV

230.62

+0.2%↑

UNH

329.49

-0.63%↓

AZN

92.7

-0.2%↓

LLY

1,083.2

+0.58%↑

JNJ

208.29

+0.39%↑

ABBV

230.62

+0.2%↑

UNH

329.49

-0.63%↓

AZN

92.7

-0.2%↓

LLY

1,083.2

+0.58%↑

JNJ

208.29

+0.39%↑

ABBV

230.62

+0.2%↑

UNH

329.49

-0.63%↓

AZN

92.7

-0.2%↓

LLY

1,083.2

+0.58%↑

JNJ

208.29

+0.39%↑

ABBV

230.62

+0.2%↑

UNH

329.49

-0.63%↓

AZN

92.7

-0.2%↓

Search

PerkinElmer Inc

Ouvert

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

50.397

78.892

BPA

0.4

Rendement du dividende

0.29

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+14.96% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.29%

2.38%

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

71M

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

40%

60%

124 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 déc. 2025, 21:41 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

28 déc. 2025, 23:57 UTC

Résultats

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

28 déc. 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 déc. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 déc. 2025, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

28 déc. 2025, 10:30 UTC

Acquisitions, Fusions, Rachats

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

26 déc. 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 déc. 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 déc. 2025, 19:24 UTC

Acquisitions, Fusions, Rachats

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 déc. 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 déc. 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26 déc. 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 déc. 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 déc. 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 déc. 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 déc. 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 déc. 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 déc. 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26 déc. 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 déc. 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 déc. 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 déc. 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 déc. 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 déc. 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 déc. 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 déc. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 déc. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 déc. 2025, 00:20 UTC

Acquisitions, Fusions, Rachats

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 déc. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 déc. 2025, 21:26 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

14.96% hausse

Prévisions sur 12 Mois

Moyen 111.22 USD  14.96%

Haut 123 USD

Bas 100 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

5

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

124 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat